Boston Scientific Revises FY23 Revenue Growth Guidance To 10.5%-11.5% (Reported) And 10%-11% (Organic) Versus 8.5%-10.5% And 8%-10% Expected Earlier; It Forecasts Adjusted EPS Of $1.96-$2.00 Vs. Consensus Of $1.95 And Prior Guidance Of $1.90-$1.96
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has revised its FY23 revenue growth guidance to 10.5%-11.5% (reported) and 10%-11% (organic), up from the previously expected 8.5%-10.5% and 8%-10%. The company also forecasts an adjusted EPS of $1.96-$2.00, higher than the consensus of $1.95 and prior guidance of $1.90-$1.96.
July 27, 2023 | 10:41 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific's revised FY23 revenue growth guidance and higher forecasted EPS could potentially lead to a positive impact on its stock price.
Boston Scientific's upward revision of its FY23 revenue growth guidance and higher forecasted EPS indicates a stronger financial performance than previously expected. This could increase investor confidence and potentially lead to a rise in the company's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100